abstract OBJECTIVE: Timely treatment with neuraminidase inhibitor (NAI) drugs appears to improve survival in adults hospitalized with influenza. We analyzed California surveillance data to determine whether NAI treatment improves survival in critically ill children with influenza.
METHODS:
We analyzed data abstracted from medical records to characterize the outcomes of patients aged 0 to 17 Of 653 cases NAI-treated, 38 (6%) died compared with 11 (8%) of 131 untreated cases (odds ratio = 0.67, 95% confidence interval: 0.34-1.36). In a multivariate model that included receipt of mechanical ventilation and other factors associated with disease severity, the estimated risk of death was reduced in NAI-treated cases (odds ratio 0.36, 95% confidence interval: 0.16-0.83). Treatment within 48 hours of illness onset was significantly associated with survival (P = .04). Cases with NAI treatment initiated earlier in illness were less likely to die.
CONCLUSIONS:
Prompt treatment with NAIs may improve survival of children critically ill with influenza. Recent decreased frequency of NAI treatment of influenza may be placing untreated critically ill children at an increased risk of death. Pediatrics 2013;132:e1539-e1545 AUTHORS: Janice K. Louie, MD, MPH, a Samuel Yang, BA, Influenza A(H1N1)pdm09 (pH1N1) virus was first identified in California in April 2009 and caused a global pandemic [1] [2] [3] that disproportionately affected children and young adults. 2 As a result, in April 2009, the California Department of Public Health (CDPH) initiated surveillance for critically ill and fatal cases of laboratory-confirmed influenza.
During the pH1N1 pandemic, the reported morbidity and mortality in California were high, with 2144 persons admitted to an ICU and 608 deaths, including 45 deaths in persons aged ,18 years. In the first few months of the pandemic, national hospitalization rates for laboratory-confirmed pH1N1 were 4.5-fold higher among children aged ,2 years, 2-fold higher among children aged 2 to 4 years, and 1.6-fold higher among children aged 5 to 17 years than among adults. 4 In California, during April 3 through August 11, 2009, of 345 persons hospitalized aged ,18 years with laboratory-confirmed influenza, more than one-quarter of these hospitalized cases required intensive care, and 9 (3%) were fatal. 5 Infants aged ,6 months were most likely to be hospitalized.
Since the onset of the pH1N1 pandemic, prompt initiation of antiviral treatment has been recommended for all patients with suspected or confirmed influenza (1) requiring hospitalization; (2) in a high-risk group with comorbidity associated with severe disease as defined by the Advisory Committee for Immunization Practices (ACIP), including children aged ,2 years; and (3) with complicated illness regardless of previous health status. The clinical efficacy and safety of oseltamivir for severe influenza in hospitalized patients have been questioned because data from phase 3 treatment trials remain unavailable for review. 9 Several observational studies have demonstrated a reduction in outcomes such as length of hospital stay and risk of critical illness requiring ICU admission or death among hospitalized adults treated with NAIs before, during, and after the pH1N1 pandemic. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] However, relatively few studies have evaluated the effectiveness of antiviral treatment of influenza in hospitalized children. We previously found that in cases aged ,18 years hospitalized with pH1N1, those treated with NAIs within 48 hours of symptom onset were less likely to require ICU admission or die compared with those never treated. 5 In this study, we analyzed antiviral treatment and survival of children aged 0 to 17 years admitted to ICUs with laboratoryconfirmed influenza reported to CDPH during the pandemic and in the 2 subsequent postpandemic influenza seasons.
METHODS
CDPH instituted mandatory reporting for all Californians who were hospitalized or died with influenza from April 3 Mantel-Haenszel adjustment was conducted and graphically assessed. Variables that may increase the severity of clinical illness that were significantly associated with fatality in univariate analysis were incorporated into a multivariable logistic regression model. Case fatality proportions were determined for cases categorized by numbers of days from onset of symptoms to initiation of antiviral therapy and were compared with those who were never treated with antiviral agents. The Cochran-Armitage test for trend was used to assess the association of survival with the time between symptom onset and initiation of antiviral treatment. All analyses were performed by using SAS 9.2 (SAS Institute, Cary, NC).
This activity was reviewed by the State of California Committee for the Protection of Human Subjects and determined to be a public health response that did not require institutional review board approval.
RESULTS
During the period of April 3, 2009, to September 30, 2012, 850 California residents aged 0 to 17 years who required intensive care or died with laboratory-confirmed influenza were reported. Of these, 827 (97%) were hospitalized in ICUs, and 23 (3%) died outside of the hospital. Overall, 784 (95%) of the hospitalized patients had information available on antiviral treatment and were analyzed.
Pandemic Versus Postpandemic
The majority of patients reported dur- (53 of 192), and influenza B in 28% (53 of 192). Overall, 532 (90%) of 591 patients reported during the pandemic received NAI treatment during their illness compared with 121 (63%) of the 193 cases in the postpandemic period (P , .0001). The interval from symptom onset to NAI treatment was similar for patients hospitalized in the pandemic period (median 3 days, range 0-33 days) and the postpandemic period (median 3 days, range 0-21 days; P = .2).
Demographic and Clinical Characteristics
Four hundred seventy-three patients (61%) were boys. The median age was 6 years (range 0 weeks-17 years). Five hundred twenty-one cases (68%) had a comorbid condition considered by the ACIP as increasing the risk of severe influenza complications 20 ; nearly half of cases had chronic pulmonary disease (366; 48%). Other frequently reported chronic medical conditions included neurologic disorders such as cerebral palsy/developmental delay and seizure disorder (277; 36%), chronic cardiac disease (105; 14%), and immunosuppression (77; 10%). The median length of hospital stay was 6 days (range 1-238 days). The median timeframes from symptom onset to hospitalization and intensive care admission were 2 days (range 0-32 days) and 3 days (range 0-372 days), respectively.
Forty-nine (6%) children died. Compared with nonfatal patients, fatal patients were more likely to have an ACIP comorbid condition (P = .005), radiographic evidence of pneumonia (P = .0007), and require mechanical ventilation (P , .0001; Table 1 ). There was no significant difference in distribution by gender, race/ethnicity, or age in the nonfatal compared with fatal cases; younger children (either ,2 or ,4 years) were not at increased risk for death.
NAI Treatment
Of the 784 patients, 653 (83%) were treated with NAIs and 131 (17%) were not. The overall median duration of NAI treatment was 5 days (range 0-16 days). Of the 653 treated patients, 38 (6%) died compared with 11 (8%) of 131 untreated patients (odds ratio [OR] = 0.67, 95% confidence interval [CI]: 0.34-1.36). In bivariate analysis stratifying on mechanical ventilation, antiviral therapy was significantly associated with decreased mortality (OR = 0.38, 95% CI: 0.17-0.87) but not in similar stratification on pneumonia (OR = 0.64, 95% CI: 0.29-1.38). In a multivariate model that incorporated variables that were significant in the univariate analysis, receipt of antiviral therapy was associated with decreased mortality (OR = 0.36, 95% CI 0.16-0.84; Table 1 ).
Timing of NAI Treatment
For the 591 (91%) cases with available information on timing of antiviral treatment, the median time from onset of symptoms to starting NAI treatment was 3 days (range 0-33 days). Of treated cases, 502 (84.9%) began treatment during their first week of illness, 66 (11.2%) during the second week and 23 (3.9%) were treated subsequently (Fig 1) . Of 255 cases treated with an NAI within 48 hours of symptom onset, 9 (3.5%) died compared with 11 (8%) of 131 untreated cases (P = .04). There was a significant difference between the median time from onset of symptoms to treatment of nonfatal cases (median 3 days, range 0-33 days) compared with fatal cases (5 days, range 0-29 days; P = .004). Early treatment with NAIs sooner after illness onset was associated with decreased mortality (Fig 1; test for trend P = .0002).
DISCUSSION
We reviewed available epidemiologic and clinical data for .780 critically ill ARTICLE children with laboratory-confirmed influenza in California over a 3-year period during and after the pH1N1 pandemic. Patients treated with NAIs were less likely to die compared with untreated patients (6% compared with 8%, respectively), suggesting NAI treatment was beneficial [OR = 0.67, 95% CI: 0.34-1.36). The risk of death in patients requiring mechanical ventilation was much higher, even when treated (OR = 81.9, 95% CI: 11.2-597.4). In a multivariate model that included receipt of mechanical ventilation and other factors associated with disease severity, the risk of dying was reduced for cases treated with NAIs (OR = 0.36, 95% CI: 0.16-0.84). Timing of NAI treatment was 7 include chronic heart disease (n = 105), chronic lung disease (n = 366), metabolic disease (n = 73), immunosuppressive conditions (n = 77), and neurologic disease (n = 277) and are not mutually exclusive. f Secondary bacterial coinfection was defined by isolation of bacteria from either a sterile site or a lower respiratory tract specimen in conjunction with a new infiltrate on chest radiograph, and excluded bacterial or fungal infections that were likely hospital-acquired (eg, diagnosed .48 h after hospital admission; Centers for Disease Control and Prevention/National Healthcare Safety Network Surveillance Definition of Healthcare-Associated Infection and Criteria for Specific Types of Infections in the Acute Care. Available at: www.cdc.gov/nhsn/pdfs/pscmanual/ 17pscnosinfdef_current.pdf). Organisms identified included methicillin-resistant Staphylococcus aureus (1), methicillin-sensitive S aureus (1), Streptococcus pneumoniae (3), Streptococcus viridans (1), Legionella pneumophila (1), and Neisseria meningitidis (1).
important: children treated earlier in their illness were less likely to die than those who were treated later, and cases treated within 48 hours of illness onset were significantly more likely to survive compared with those never treated.
There is strong evidence that NAI treatment of hospitalized adults is beneficial when initiated early in the clinical course of influenza, although evidence from randomized placebocontrolled trials is lacking. 20 In large observational studies, hospitalized adults infected with seasonal, pH1N1 or influenza A (H5N1) viruses were less likely to die or require intensive care when NAIs were initiated no later than 4 days from onset of symptoms. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Initiation of NAI treatment within 5 days of symptom onset increased the likelihood of survival in a study of .1800 adults hospitalized in ICUs in California. 21 A recent meta-analysis reviewing data from 90 studies of adults and children with pH1N1 found NAI treatment within 48 hours of symptom onset reduced the likelihood of severe outcomes such as death and ICU admission. 22 There are fewer and less consistent data on the effectiveness of NAI treatment of influenza in hospitalized children, with some studies finding no association with improved survival. Early NAI use in hospitalized children has been associated with a decreased likelihood of ICU admission and need for mechanical ventilation; mortality was not assessed in these studies. 23, 24 A study of 287 hospitalized, previously healthy children found no difference in length of stay, diagnosis of pneumonia, ICU admission or death in NAItreated compared with untreated patients; however, the young age of patients (40% aged ,6 months) may have prompted hospitalization for observation purposes rather than because of severity of illness. 25 A retrospective cohort study of .500 children with severe seasonal influenza illness admitted to PICUs over 6 influenza seasons (2001) (2002) (2003) (2004) (2005) (2006) (2007) found that patients treated with oseltamivir within 24 hours of hospital admission had an 18% reduction in total hospital days (P = .02) but no significant reduction in length of PICU stay, in-hospital mortality, and readmission rates. 26 In contrast, a handful of small studies have suggested that early NAI treatment improves survival. During the initial phase of the 2009 H1N1 pandemic, initiation of oseltamivir within 48 hours of symptom onset was associated with a decreased likelihood of ICU admission or death (P = .02) in 345 children hospitalized in California. 5 Oseltamivir treatment initiated within 24 hours of hospitalization was protective against death (P = .02) for 147 critically ill children in Argentina. 27 Delayed initiation of oseltamivir increased the likelihood of death for 193 children hospitalized with highly pathogenic avian influenza A (H5N1) virus infection, with a 75% increase in the adjusted OR for death for each day of delay. 28 Likewise, our review of nearly 800 critically ill children with influenza patients suggests improvement in survival with prompt NAI treatment.
Of note, frequency of NAI treatment in our ICUs was 90% during the pandemic but fell to 63% in the following 2 years. 30 Finally, our results likely represent patients infected with influenza viruses susceptible to NAIs because only 3 of 423 cases tested in California during this surveillance period were infected with influenza viruses containing the H275Y mutation in neuraminidase, which confers resistance to oseltamivir (CDPH, unpublished data).
Our results suggest that prompt NAI therapy in children with influenza virus infection who are hospitalized in an ICU may improve survival, including in those most severely ill who require mechanical ventilation. These findings also emphasize the need for, and the difficulty in obtaining, better evidence of the efficacy and optimal timing of NAI therapy in children; large randomized controlled trials of NAIs could provide better evidence, but at great expense, and present ethical issues because current guidelines recommend initiation of NAI treatment as soon as possible in hospitalized children with influenza. 7 Nevertheless, prompt initiation of NAIs seems prudent in a critical care setting where the likelihood of severe morbidity and mortality outweighs concern for side effects. This message needs additional emphasis given that in this study, more than one-third of critically ill children with influenza did not receive antiviral treatment in the postpandemic period.
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